Beta Bionics, Inc. (NASDAQ:BBNX – Get Free Report) Director Adam Lezack sold 998 shares of the stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $11.21, for a total transaction of $11,187.58. Following the transaction, the director owned 27,399 shares in the company, valued at approximately $307,142.79. The trade was a 3.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Adam Lezack also recently made the following trade(s):
- On Thursday, May 21st, Adam Lezack sold 1,000 shares of Beta Bionics stock. The stock was sold at an average price of $9.95, for a total transaction of $9,950.00.
Beta Bionics Stock Down 0.8%
Shares of BBNX stock traded down $0.10 during trading hours on Tuesday, hitting $11.72. 795,893 shares of the company were exchanged, compared to its average volume of 1,168,092. The firm has a market cap of $522.24 million, a PE ratio of -7.76 and a beta of 3.29. Beta Bionics, Inc. has a 1 year low of $8.80 and a 1 year high of $32.71. The firm has a fifty day moving average of $10.62 and a 200 day moving average of $18.03.
Wall Street Analyst Weigh In
Several research analysts have recently weighed in on the stock. The Goldman Sachs Group cut their price objective on shares of Beta Bionics from $23.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday, April 9th. Leerink Partners cut their price objective on shares of Beta Bionics from $25.00 to $24.00 and set an “outperform” rating on the stock in a report on Wednesday, April 22nd. Lake Street Capital set a $20.00 target price on shares of Beta Bionics in a research report on Wednesday, February 18th. Stifel Nicolaus dropped their target price on shares of Beta Bionics from $22.00 to $20.00 and set a “buy” rating for the company in a research report on Wednesday, April 22nd. Finally, Truist Financial dropped their target price on shares of Beta Bionics from $25.00 to $18.00 and set a “buy” rating for the company in a research report on Wednesday, April 15th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $20.00.
Read Our Latest Report on Beta Bionics
Institutional Trading of Beta Bionics
A number of institutional investors and hedge funds have recently bought and sold shares of BBNX. GPS Wealth Strategies Group LLC increased its position in Beta Bionics by 45.0% during the 3rd quarter. GPS Wealth Strategies Group LLC now owns 1,450 shares of the company’s stock worth $29,000 after purchasing an additional 450 shares in the last quarter. Strs Ohio acquired a new stake in Beta Bionics during the 1st quarter worth approximately $29,000. EverSource Wealth Advisors LLC increased its position in Beta Bionics by 203.6% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock worth $47,000 after purchasing an additional 1,594 shares in the last quarter. Summit Securities Group LLC acquired a new stake in Beta Bionics during the 4th quarter worth approximately $52,000. Finally, Legal & General Group Plc increased its position in Beta Bionics by 197.4% during the 2nd quarter. Legal & General Group Plc now owns 3,976 shares of the company’s stock worth $58,000 after purchasing an additional 2,639 shares in the last quarter.
Beta Bionics Company Profile
Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.
At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.
Featured Articles
- Five stocks we like better than Beta Bionics
- Banks Are Buying Back Stock Hand Over Fist, Including These 3 Names
- 2 Aluminum Stocks Poised for Big Tariff-Related Gains
- AutoZone’s Pullback Sets Up a Long-Term Buying Opportunity
- AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus
Receive News & Ratings for Beta Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beta Bionics and related companies with MarketBeat.com's FREE daily email newsletter.
